A61K 39/39591
Stabilisation, fragmentation
Official title: {Stabilisation, fragmentation}
A61K39/39591 (Stabilisation, fragmentation) appears on 988 US grants and 2,094 published applications in this corpus.
Search patents in A61K- Granted patents
- 988
- Published applications
- 2,094
- Assignees
- 583
- Inventors
- 3,432
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 2 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 1 | 0 |
| 1999 | 6 | 0 |
| 2000 | 2 | 0 |
| 2001 | 6 | 2 |
| 2002 | 1 | 2 |
| 2003 | 2 | 14 |
| 2004 | 3 | 14 |
| 2005 | 3 | 16 |
| 2006 | 4 | 14 |
| 2007 | 2 | 19 |
| 2008 | 6 | 28 |
| 2009 | 5 | 32 |
| 2010 | 12 | 42 |
| 2011 | 8 | 47 |
| 2012 | 15 | 52 |
| 2013 | 21 | 84 |
| 2014 | 52 | 88 |
| 2015 | 56 | 113 |
| 2016 | 65 | 119 |
| 2017 | 78 | 120 |
| 2018 | 57 | 112 |
| 2019 | 65 | 133 |
| 2020 | 74 | 123 |
| 2021 | 73 | 168 |
| 2022 | 64 | 136 |
| 2023 | 75 | 165 |
| 2024 | 79 | 169 |
| 2025 | 77 | 150 |
| 2026 | 50 | 132 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Preparation comprising anti-PCSK9 antibody and use thereof22 Sep 2026US 12,741,023 B2Innovent Biologics (Suzhou) Co., Ltd.
- Pharmaceutical products and stable liquid compositions of IL-17 antibodies22 Sep 2026US 12,741,024 B2Novartis AG
- Liquid pharmaceutical composition comprising an anti-il-6 receptor antibody22 Sep 2026US 12,742,014 B2Fresenius Kabi Deutschland GmbH
- Formulation comprising anti-IL-23P19 antibody, method for preparing same and use thereof15 Sep 2026US 12,734,237 B2Innovent Biologics (Suzhou) Co., Ltd.
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Risankizumab compositions1 Oct 2026US 2026/0297178 A1AbbVie Inc.
- Methods for the treatment of t-cell acute lymphoblastic leukemia24 Sep 2026US 2026/0284190 A1Centre National De La Recherche Scientifique
- Risankizumab compositions24 Sep 2026US 2026/0285967 A1AbbVie Inc.
- Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof17 Sep 2026US 2026/0273052 A1Genentech, Inc.
Most cited
By later US patents
- Antibody formulation655US 6,171,586 B2Genentech, Inc. · 2001
- Protein formulation586US 6,267,958 B1Genentech, Inc. · 2001
- Dispersible antibody compositions and methods for their preparation and use351US 6,019,968 AInhale Therapeutic Systems · 2000
- Human antibodies that bind human IL-12 and methods for producing300US 6,914,128 B1Abbott GmbH & Co. KG · 2005
- Anti-PD1 antibodies and their use as therapeutics and diagnostics285US 8,735,553 B1BeiGene, Ltd. · 2014